TNFRSF18 and colorectal cancer: As depicted in Figure 1C, we observed comparable expression of both molecules on Treg cells from healthy donors and colorectal cancer patients while percentages of CD4+CD25highFOXP3+ Treg cells expressing either molecule were significantly increased in colorectal cancer patients (CTLA4: 3.7%±1.2% vs. 1.5%±0.6%, p<0.001; GITR: 1.7%±0.8% vs. 0.5%±0.2%, p<0.001) (Fig. 1D).